SULIQUA (insulin glargine/ lixisenatide), antidiabetic

Insufficient clinical benefit to justify reimbursement for type 2 diabetes

• SULIQUA has been granted marketing authorisation for the treatment of type 2 diabetes, to improve glycaemic control, in combination with metformin, when metformin, alone or combined with another oral antidiabetic, or with basal insulin is unable to provide adequate glycaemic control.

• The available clinical data fail to demonstrate the clinical benefit of combining SULIQUA with metformin in terms of reduction in HbA1c, reduction in insulin consumption or in morbidity and mortality compared to an insulin multi-injection scheme.

• SULIQUA has no role in the therapeutic strategy for type 2 diabetes.